CD19 and B-cell non-Hodgkin lymphoma: CD38, like CD19 due to its wide distribution on B-NHL cells, is an ideal molecular target for the treatment of this malignancy and, as previously reported, so far, no side effects following treatment with anti-CD38 Ab in B cell lymphoma patients has been reported (230).